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Abstract
Monocytes and macrophages play key roles in many disease states, including cellular and
humoral rejection after solid organ transplantation (SOT). To suppress alloimmunity after
SOT, immunosuppressive drug therapy is necessary. However, little is known about the
effects of the immunosuppressive drugs tacrolimus and mycophenolic acid (MPA) on mono-
cyte activation and function. Here, the effect of these immunosuppressants on monocytes
was investigated by measuring phosphorylation of three intracellular signaling proteins
which all have a major role in monocyte function: p38MAPK, ERK and Akt. In addition, bio-
logical functions downstream of these signaling pathways were studied, including cytokine
production, phagocytosis and differentiation into macrophages. To this end, blood samples
from healthy volunteers were spiked with diverse concentrations of tacrolimus and MPA.
Tacrolimus (200 ng/ml) inhibited phosphorylation of p38MAPK by 30% (mean) in CD14+
monocytes which was significantly less than in activated CD3+ T cells (max 60%; p < 0.05).
This immunosuppressive agent also partly inhibited p-AKT (14%). MPA, at a therapeutic
concentration showed the strongest effect on p-AKT (27% inhibition). p-ERK was inhibited
with a maximum of 15% after spiking with either tacrolimus or MPA. The production of IL-1β
and phagocytosis by monocytes were not affected by tacrolimus concentrations, whereas
MPA did inhibit IL-1β production by 50%. Monocyte/macrophage polarization was shifted to
an M2-like phenotype in the presence of tacrolimus, while MPA increased the expression of
M2 surface markers, including CD163 and CD200R, on M1 macrophages. These results
show that tacrolimus and MPA do not strongly affect monocyte function, apart from a
change in macrophage polarization, to a clinically relevant degree.
Introduction
Monocytes have numerous biologic functions that make them key players in solid organ trans-
plantation (SOT)-related conditions, including ischemia-reperfusion injury and its repair, as
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well as regulation of allograft rejection [1–5]. After SOT, cells of the monocyte/macrophage
lineage, process and present alloantigen to the recipients’ immune system, induce inflamma-
tion and contribute to allograft rejection, through the secretion of pro-inflammatory cytokines
and by providing help to alloreactive T- and B-cells. For example, after ischemia and reperfu-
sion injury, monocytes infiltrate the allograft where, after differentiation into macrophages,
they produce inflammatory cytokines, can present donor antigen and also contribute to tissue
injury and repair processes [6]. Furthermore, immunohistochemistry of acute rejection kidney
specimens demonstrated massive infiltration of the transplanted organ by CD68+ monocyte/
macrophages [3, 7]. In antibody-mediated rejection, monocytes control and induce cell injury
via the activation of their Fcγ-receptor by allo-antibodies [8, 9]
In tissue, monocytes differentiate into different macrophages subsets depending on the
environmental cues the cells encounter. In general, classically and alternatively activated mac-
rophages, termed M1 and M2 macrophages, respectively, represent the ends of a spectrum and
can be distinguished by a unique set of cell surface markers [10–12]. Typically, M1 macro-
phages have a pro-inflammatory function and secrete large amounts of IL-12 and low levels of
IL-10, while M2 macrophages can be divided into functionally different subsets. M2a macro-
phages are involved in T-helper type 2 (Th2) immune responses and have pro-fibrotic proper-
ties. M2b macrophages are considered immunoregulatory because they secrete large amounts
of IL-10 in combination with TNF-α, IL-1 and IL-6 [13]. Just like the M2a cells, M2b macro-
phages are also involved in Th2 immune responses [14]. M2c macrophages are anti-inflamma-
tory and characterized by their capacity to produce large amounts of TGF-ß and IL-10 [14,
15].
Despite their clinical importance, surprisingly little is known about the effects of immuno-
suppressive drugs on monocyte/macrophage differentiation and function. Currently, most
kidney transplant recipients, as well as the majority of recipients of other solid organ trans-
plants receive combination immunosuppressive therapy consisting of tacrolimus and myco-
phenolic acid (MPA; either in the form of mycophenolate mofetil or mycophenolate-sodium)
[16–24]. In addition, tacrolimus has also shown to be effective in the treatment of patients
with ulcerative colitis and atopic dermatitis [25–28] while MPA is used for the treatment of
auto-immune disease such as systemic lupus erythematosus [29]. The limited number of stud-
ies on the effect of tacrolimus on monocyte functions have been mostly performed in animal
models, immortalized cell lines and cord blood cells. These studies report that tacrolimus can
suppress the production of IL-1β, IL-10 and TNF-α by polyclonally activated monocytes [26,
30, 31].
A limited number of studies report on the effects of MPA on macrophage functions. The
study by Weimer et al. showed that MPA can suppress the production of IL-1β and IL-6 by
staphylococcal superantigens activated monocytes, while the effects of MPA on phagocytosis
and monocyte differentiation are unknown [32].
Monocyte/macrophage responses to environmental triggers are controlled by the activation
of multiple intracellular signaling pathways, in which p38 mitogen-activated protein kinases
(p38MAPK), extracellular signal-regulated kinases (ERK) and Akt play important roles (Fig 1)
[33–36]. Activation of these pathways initiates a complex cascade leading to binding of tran-
scription factors to DNA followed by cytokine gene expression and production, phagocytosis
and other functions. Previous studies in T-lymphocytes have demonstrated that tacrolimus
does not only inhibit the calcineurin pathway, but also affects the MAPK pathway, while the
effects of MPA are unknown [37]. It is unknown if immunosuppressive drugs also inhibit
these same pathways in monocytes, and affect related biological functions.
Given the important role of monocytes in immune responses after SOT, the effects on
monocyte function of the two most commonly prescribed immunosuppressive agents,
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tacrolimus and MPA, have been studied. Monocytes have been studied in peripheral blood
samples of healthy volunteers that were incubated with tacrolimus or MPA and subsequently
their activation, signal transduction, phenotypic differentiation, phagocytic capacity and cyto-
kine production upon PMA/ionomycin stimulation were investigated.
Materials and Methods
In vitro phosphorylation study and whole-blood phospho-specific
flowcytometry
To measure the effect of tacrolimus and MPA on signaling molecules, heparinized blood sam-
ples were drawn from healthy volunteers (n = 5). The study protocol was approved by the local
ethics committee of the Erasmus medical center and written informed consent was obtained
from each individual after receiving detailed information about the aims of the study. Samples
were incubated for one hour at 37˚C with either vehicle, tacrolimus (10, 50 or 200 ng/ml; Pro-
graf1, Astellas Pharma Inc., Tokyo, Japan), MPA (10 μg/ml; Sigma-Aldrich, Steinheim, Ger-
many) or the p38MAPK inhibitor SB203580 (20 μM; Invivogen, San Diego, CA). The vehicle
used was IMDM medium (Gibco BRL, Carlsbad, CA) supplemented with 10% heat-inactivated
fetal bovine serum (BioWhittaker, Verviers, Belgium). Phosphorylation of p38MAPK, ERK
Fig 1. Simplified overview of intracellular signaling pathways involved in monocyte activation. After
toll like receptor (TLR) or FC-γ receptor activation the MAPK, Akt and NFAT pathways are activated
upstream. The phosphorylation of the intracellular signaling proteins leads to the activation of transcription
factors, such as CREB and NF-κB p65, which after activation leads to gene transcription. This process
determines the function of monocytes including phenotypic differentiation, cytokine production and
phagocytosis.
doi:10.1371/journal.pone.0170806.g001
Effect of Tacrolimus and Mycophenolic Acid on Monocyte Functions
PLOS ONE | DOI:10.1371/journal.pone.0170806 January 25, 2017 3 / 19
and Akt was measured according to the manufacturer’s instructions for phosphoprotein analy-
sis (BD Biosciences, San Jose, CA). In brief, 200 μl heparinized blood was stained with Brilliant
Violet (BV)510-labelled mouse anti-human CD3 (Biolegend, San Diego, CA) and Fluorescein
Isothiocyanate (FITC)-labelled mouse anti-human CD14 (Serotec, Oxford, UK) for 30 min-
utes at 37˚C. After 15 minutes, blood samples were activated with PMA/ionomycin (25 μg per
ml/500 μg per ml for p38MAPK and Akt; 5 μg per ml/100 μg per ml for ERK, Sigma-Aldrich,
Steinheim, Germany) for 15 minutes. To compare phosphorylation of p38MAPK in CD3+ T-
cells and CD14+ monocytes, samples were also stimulated for 30 minutes with PMA/ionomy-
cin. Then cells were fixed for 10 minutes with Lyse/Fix buffer (BD Biosciences) and permeabi-
lized with 90% methanol at -20˚C for 30 minutes. Samples were stained intracellular with
fluorchrome conjugated mAb phycoerythrin (PE)-labelled mouse anti-p38MAPK (clone
pT180/pY182), PE-labelled mouse anti-pAkt (clone pS473) or AlexaFluor647 (AF647)-labelled
mouse anti-pERK1/2 (pT202/pY204) (all from BD Biosciences) for 30 minutes at room tem-
perature and analyzed on a FACS Canto II flowcytometer (BD Biosciences). Unstimulated
samples were used as negative controls. Isotype controls; mouse IgG1-PE (p38, Akt Biolegend)
and mouse IgG1-AF647 (ERK; Biolegend); were included in separated tubes. Interday-vari-
ability of the flowcytometer was corrected by using Cytocalbeads (Thermo Scientific, Fremont,
CA) according to the manufacturer’s instructions.
Cytokine production
Heparinized blood samples from healthy volunteers were incubated for 1 hour at 37˚C with
either vehicle, tacrolimus (10 ng/ml and 50 ng/ml), MPA (10 μg/ml) and activated with PMA/
ionomycin (25 μg per ml/400 μg per ml) for four hours at 37˚C. Golgiplug (BD Biosciences)
was added during the incubation phase to accumulate cytokines intracellularly. Subsequently,
EDTA was added for 15 minutes to stop activation. Cells were then stained with BV510-la-
belled mouse anti-human CD3 (Biolegend) and FITC-labelled mouse anti-human CD14 (Ser-
otec) for 30 minutes at 37˚C, fixed for 10 minutes with FACS lysing solution (BD Biosciences)
and treated with permeabilization buffer II (BD Biosciences) for 10 min. AF647-labelled anti-
IL-1β (detecting the bioactive form of IL-1β, 17.3 kD, clone JK1B-1, BD Biosciences) was used
for intracellular cytokine staining for 30 minutes at 4˚C.
Phagocytosis
To assess phagocytosis by monocytes, whole-blood samples of healthy volunteers were incu-
bated for 1 hour at 37˚C with either vehicle, tacrolimus (10, 50 and 200 ng/ml) or MPA (10 μg/
ml). Then 100 μl of spiked blood per sample was tested for phagocytosis according to the man-
ufacturer’s instructions of the Phagotest (Glycotope Biotechnology, Heidelberg, Germany),
which used FITC- labelled E. coli-bacteria.
Macrophage phenotypic differentiation
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood samples by
density-gradient centrifugation using Ficoll-paque (GE Healthcare, Uppsala, Sweden). Subse-
quently, monocytes were isolated by MACS magnetic cell separation (Miltenyi Biotec, Bergisch
Gladbach, Germany) using anti-human CD14 magnetic microbeads (Miltenyi). Then, mono-
cytes were cultured in a 12 wells plate at a concentration of 75 x104 cells/ml in RPMI 1640 cul-
ture medium with glutaMAX and 25 mM HEPES (Gibco, Life technologies, Paisley, UK),
supplemented with 10% heat inactivated fetal bovine serum (FBS, BioWhittaker, Verviers, Bel-
gium) and M-CSF (macrophage colony-stimulating factor; 5ng/ml, Bioconnect, Huissen, the
Netherlands). As positive controls, cells were polarized with recombinant human IFN-γ, IL-10
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and IL-4 (all 50 ng/ml, Bioconnect) according to Ambarus et al. [38]. Effects of immunosup-
pressive drugs on monocyte differentiation were examined by culturing monocytes in the
presence of either vehicle, tacrolimus (10 ng/ml and 50 ng/ml) or MPA (10 μg/ml). At baseline
(day 0) and after 4 days of differentiation, monocytes were tested for their polarization profile
after incubation on ice for 1 h by using the following markers [38]: BV421-labelled mouse
anti-human CD80 (Biolegend), FITC-labelled mouse anti-human CD163 (Serotec), allophyco-
cyanin (APC)-H7-labelled mouse anti-human CD14 (BD Biosciences), BV510-labelled mouse
anti-human CD64 (BD Biosciences), PE-Cyanine7 (PE-Cy7)-labelled mouse anti-human
CD16 (BD Biosciences), peridinin-chlorophyll-protein (PERCP)-labelled mouse anti-human
CD200R (eBioscience, Vienna, Austria) and APC-labelled rat anti-mouse/human CD11b (Bio-
legend). Unstained samples were used as a negative control. Background fluorescence levels of
isotype controls were used as negative reference.
Data analysis and statistics
The phosphorylation of p38MAPK, Akt and ERK was measured as the Median Fluorescence
Intensity (MFI) and normalized using Cytocalbeads (Thermo Scientific). MFI values of the
unstimulated samples were subtracted from the stimulated MFI values. Data and statistical
analysis was performed with Diva-version 6.0 software (BD Biosciences) and Graph Pad Prism
5.0 (Graph Pad Software Inc., La Jolla, CA) by using paired t-tests (for the in vitro phosphory-
lation study after performing log transformation and after finding a p-value >0.05 with an F-
test). A two-sided p-value < 0.05 was considered statistically significant.
Results
Inhibitory effect of tacrolimus and MPA in monocyte signaling pathway
activation
A typical example of monocytes (CD14+) and T-cells (CD3+) gating strategies is depicted in
Fig 2A. In line with previous observations, activation of whole blood samples by PMA/iono-
mycin significantly increased the expression of phosphorylated p38MAPK in CD3+ T-cells
compared to the ex vivo (unstimulated) whole blood level and isotype controls [37] (Fig 2B
and 2C). In CD14+ monocytes, an increase in phosphorylation levels after stimulation was
observed for p38MAPK, ERK and Akt compared to the isotype controls and ex vivo samples
(Fig 2D and 2E). Again, this increase is in line with previous studies [39–41].
To study the effect of tacrolimus on CD3+ T-cells and CD14+ monocytes, cells were incu-
bated with tacrolimus in a dose dependent manner. In this study, T-cell p38MAPK phosphory-
lation levels served as controls. At a high concentration (200 ng/mL), tacrolimus inhibited p-
p38MAPK in T-cells with a mean of 60%, which was significantly higher than the percentage
of inhibition in monocytes (30%, p< 0.05) (Fig 3). For the monocytes this was not different
over time.
Next, the effect of tacrolimus and MPA on the phosphorylation of each signaling protein in
CD14+ monocytes was measured and compared to the phosphorylation in the samples with-
out drugs. The p38MAPK inhibitor SB203580, used as a control, showed the maximal inhibi-
tory effect on p38MAPK phosphorylation (inhibition 48%; p< 0.001, Fig 4A and 4B). Apart
from the effect on p38MAPK, SB203580 also suppressed the phosphorylation of ERK (mean
inhibition 13%; p< 0.05), and Akt (mean inhibition 59%; p< 0.001).
In the presence of high tacrolimus concentrations (50 ng/ml, 200 ng/ml), phospho-
p38MAPK was significantly lower expressed (p< 0.05 and p< 0.01, respectively) than in the
samples without tacrolimus Fig 4A). This decrease was not seen in the presence of a therapeutic
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Fig 2. Gating strategy for the selection of monocytes and T-cells, and the measurement of p38MAPK,
ERK and Akt phosphorylation. (A) Scatter dot plots to define the monocyte population in blood samples from
healthy controls. Cells were selected in whole blood samples for each healthy control and then gated for their
expression of either CD3 or CD14. Then, CD3+ and CD14+ cells were combined in one dotplot, to make sure
that there were no double positive cells in the analysis. (B) An example of p38MAPK phosphorylation in CD3+ T
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tacrolimus concentration (10 ng/ml). The mean maximal p38MAPK phosphorylation inhibi-
tion in monocytes was 30% and 33% at 50 and 200 ng/ml tacrolimus, respectively (Fig 4B). Fur-
thermore, in the presence of 200 ng/ml tacrolimus the PMA/iono activated phosphorylation of
both ERK and Akt were suppressed, although with small percentages (mean 7% and 14%,
respectively, p< 0.05, Fig 4) On the other hand, MPA (10 μg/ml) downregulated p-ERK and p-
AKT (mean inhibition 14% and 27%, respectively, p< 0.01), but not phospho-p38MAPK
(p = 0.51, Fig 4).
Taken together, these experiments demonstrate that tacrolimus at high concentrations
inhibits phosphorylation of p38MAPK more than Akt and ERK, while at therapeutic concen-
trations, tacrolimus did not affect the activation of these molecules. In addition, MPA sup-
presses the phosphorylation of Akt more than the phosphorylation of ERK or p38MAPK.
IL-1β production decreased in the presence of MPA but not after
tacrolimus spiking
The percentage of IL-1β-producing cells was studied to determine whether the significant
alterations in phosphorylation of the MAPK pathway members p38 and ERK by tacrolimus
has an effect on cytokine production by monocytes. Again, whole blood samples were stimu-
lated with PMA/ionomycin after which IL-1β protein expression was measured (Fig 5A). After
cells, measured as the median fluorescence intensity (MFI) prior to (ex vivo) or after stimulation with PMA/
ionomycin (in vitro) compared to the isotype control. (C) p38MAPK phosphorylation in CD3+ T-cells was
increased after stimulation with PMA/ionomycin compared to isotype controls and ex vivo (unstimulated)
samples. (D) Examples of the phosphorylation of p38MAPK, Akt and ERK in CD14+ monocytes of isotype
controls, ex vivo (unstimulated) and PMA/Ionomycin stimulated (in vitro) samples. (E) Phosphorylation (MFI) of
p38MAPK, Akt and ERK in CD14+ monocytes is increased after PMA/ionomycin stimulation compared to
isotype controls and ex vivo samples and showed the maximum phosphorylation capacity for each protein. FSC,
forward scatter; SSC, side scatter; MFI, median fluorescence intensity. (Data are plotted as the mean ±SEM;
n = 5.)
doi:10.1371/journal.pone.0170806.g002
Fig 3. p38MAPK phosphorylation is inhibited more in T-cells than in monocytes. Blood samples from
healthy volunteers were spiked with either vehicle, 10 ng/ml tacrolimus, 50 ng/ml tacrolimus or 200 ng/ml
tacrolimus. Thereafter, the phosphorylation of p38MAPK was determined in T-cells and monocytes after 15 or
30 min. of stimulation with PMA/ionomycin. After 30 min. stimulation, T-cells were significantly more inhibited
than monocytes. (Data are plotted as the mean ±SEM; n = 3) *) p < 0.05; **) p < 0.01; ***) p < 0.001.
doi:10.1371/journal.pone.0170806.g003
Effect of Tacrolimus and Mycophenolic Acid on Monocyte Functions
PLOS ONE | DOI:10.1371/journal.pone.0170806 January 25, 2017 7 / 19
Fig 4. Tacrolimus and MPA can inhibit signaling pathway activation in whole-blood samples. (A) Phospho-p38MAPK
(upper left panel), p-ERK (upper right panel) and p-Akt (lower panel) phosphorylation in monocytes was measured as MFI
level. Blood samples from healthy volunteers were spiked with vehicle, 10 ng/ml tacrolimus, 50 ng/ml tacrolimus, 200 ng/ml
tacrolimus, 10 μg/ml MPA or 20 μM of the MAPK inhibitor SB203580. The effect of tacrolimus and MPA was based on the
stimulated samples without the addition of drugs. The MAPK inhibitor was used as a positive control. Gating was performed
according to Fig 2. Tacrolimus was found to have an effect on p38MAPK, ERK and Akt phosphorylation. Akt and ERK
phosphorylation was decreased in the presence of MPA. (B) Percentages of inhibition for the phosphorylation of p38MAPK
(upper left panel), ERK (upper right panel) and Akt (lower panel). Data are normalized for the MFI values of the stimulated
samples without the addition of immunosuppressive drugs. (Data are plotted as the mean ±SEM; n = 5) *) p < 0.05;
**) p < 0.01; ***) p < 0.001.
doi:10.1371/journal.pone.0170806.g004
Effect of Tacrolimus and Mycophenolic Acid on Monocyte Functions
PLOS ONE | DOI:10.1371/journal.pone.0170806 January 25, 2017 8 / 19
stimulation, more than 10% of the monocytes expressed the 17.3 kD form of IL-1β, which is
the active IL-1β protein (in contrast to the 31kD precursor protein which is not biologically
active). No significant change in IL-1β protein expression was found when blood samples were
spiked with tacrolimus at either a therapeutic concentration (10 ng/ml, p = 0.28) or a concen-
tration of 50 ng/ml or 200 ng/ml (p = 0.36 and p = 6758, respectively) (Fig 5B). A significantly
lower percentage of IL-1β-producing cells was found in the presence of 10 μg/ml MPA (about
50% inhibition; p< 0.05).
Effects of tacrolimus and MPA on phagocytosis by monocytes
Subsequently, phagocytosis, one of the primary biological functions of monocytes, was studied
in the presence and absence of immunosuppressive drugs. The percentage of monocytes that
phagocytized labeled bacteria after incubation at 37˚C, was more than 90% (Fig 6). This per-
centage was not influenced by tacrolimus at therapeutic (10 ng/ml, p = 0.44) or high (50 ng/
ml, p = 0.29 and 200 ng/ml, p = 0.33) concentrations nor by a high concentration of MPA
(10 μg/ml, p = 0.45).
Fig 5. IL-1β production by monocytes of healthy controls is suppressed in the presence of MPA but
not in the presence of tacrolimus. (A) Dot plots showing IL-β production with or without stimulation in
monocytes. Cells were gated of whole blood samples according to Fig 2a. Isotype controls were used as
negative controls and were used to set the gate for the positive IL-1β expression. Results are shown as the
percentage of IL-1β producing monocytes compared to the isotype control. Samples were stimulated with
PMA/ionomycin for maximum production of IL-1β. (B) Mean percentages of IL-1β producing monocytes after
spiking with vehicle, 10 ng/ml tacrolimus, 50 ng/ml tacrolimus or 10 μg/ml MPA. Samples were corrected for
the unstimulated results and then normalized to the samples without drug exposure. IL-1β production in
monocytes was significantly suppressed by a concentration of 10 μg/ml MPA. (Data are plotted as the mean
±SEM; n = 5) *) p < 0.05.
doi:10.1371/journal.pone.0170806.g005
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Phenotypic macrophage differentiation is influenced by tacrolimus and
MPA
After stimulation with M-CSF, freshly isolated monocytes differentiate into M1 or M2 subsets
when additionally treated with the appropriate triggers (a schematic flow diagram of these
experiments is given in S1A Fig). In line with previously published data, M1 macrophages had
a higher expression of CD80 and CD64, M2a macrophages had a lower expression of CD14
and a higher expression of CD200R, and M2c macrophages had a higher expression of CD163
and CD16 on their surface compared to macrophages cultured without the addition of cyto-
kines (S1B Fig) [38].
Differentiation of monocytes/macrophages can be divided into two processes: maturation of
the monocyte into a macrophage and the subsequent polarization of a macrophage into an M1
or M2 type. First, the effect of tacrolimus and MPA on monocyte maturation was studied. After
maturation of monocytes under M-CSF culture conditions only, the expression of all six tested
markers increased significantly (Fig 7). During maturation, tacrolimus (10 ng/ml), but not MPA,
slightly increased the expression of CD200R and CD16 (both markers for M2 macrophages,
p< 0.05 Fig 7), compared to the maturation without the presence of immunosuppressive drugs.
Fig 6. The percentage of phagocytosis by monocytes from healthy controls was not changed in the
presence of tacrolimus or MPA. (A) Monocytes were selected from the leukocyte population by a forward
and side scatter. Analysis was based on the phagocytosis of the FITC-labeled bacteria. Incubation with FITC-
labeled bacteria on 37˚C showed a high percentage of phagocytosing monocytes (positive control) compared
to monocytes on 0˚C (negative control). (B) Mean percentage of phagocytosing monocytes after spiking with
either vehicle, 10 ng/ml tacrolimus, 50 ng/ml tacrolimus, 200 ng/ml tacrolimus or 10 μg/ml MPA. Incubation at
37˚C increased the percentage of phagocytosing monocytes by more than 90%. Effects of tacrolimus and
MPA on phagocytosis were determined as the percentage of phagocytosing monocytes compared to the
positive control without immunosuppressive drugs. (Data are plotted as the mean ±SEM; n = 4).
doi:10.1371/journal.pone.0170806.g006
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A high concentration of tacrolimus (50 ng/ml) also increased the expression of CD16 (MFI
increase: 5692 to 6607 p< 0.05). Second, the polarization of these mature macrophages was
determined. The addition of IFN-γ, IL-4 and IL-10 was used as a positive control for the differen-
tiation assays to compare the polarization of the macrophages after their maturation from mono-
cytes. An increase of CD200R and CD16 expression on monocytes was seen after the addition of
IL-4 and IL-10 to the culture medium, which are both stimuli to induce M2 macrophages (S1B
Fig). Thus, tacrolimus increased the expression of markers for M2 macrophages, while this was
not seen for MPA.
Next, the influence of tacrolimus and MPA on the polarization of macrophage subsets was
determined, by measuring the expression of M1- and M2-related surface markers. Monocytes
were cultured for 4 days in the presence of M-CSF as a maturation stimulus supplemented
with M1 (IFN-γ), M2a (IL-4), and M2c (IL-10) stimulants and different concentrations of
tacrolimus or MPA.
In the presence of IFN-γ, a stimulus for M1, the addition of tacrolimus (50 ng/ml and 200
ng/ml) led to the increased expression of the M2 marker CD16 (p< 0.01 and p< 0.05, respec-
tively) and a lower expression of CD14 (p< 0.05 and p< 0.01, respectively, Fig 8, left column).
In addition, tacrolimus at a therapeutic concentration (10 ng/ml) also lowered CD14 expres-
sion (p< 0.05). MPA caused a significant increase of the other two M2 markers, CD200R and
CD163 (p< 0.05) and, although not significant, seemed to lower the expression of the M1
markers CD80 and CD64.
In the presence of the M2a stimulus IL-4, high concentrations of tacrolimus (50 and 200
ng/ml) increased the expression of CD163, although this difference was small (MFI: from 3906
to 3958 and 3957, respectively, p< 0.05, Fig 8, middle column). MPA significantly decreased
the expression of CD80 (M1 marker, p< 0.05).
Fig 7. Monocyte differentiation in the presence of tacrolimus and MPA causes a small shift in macrophages subsets. CD14+ monocytes
were freshly isolated from whole blood samples of healthy volunteers (n = 5) and then cultured for 4 days with either vehicle, 10 ng/ml tacrolimus,
50 ng/ml tacrolimus, 200 ng/ml tacrolimus or 10 μg/ml MPA. The addition of cytokines was used a positive control. Differentiated macrophages
were gated based on their location on the forward sideward scatter. After 4 days of culturing, the expression of all tested surface markers was
increased compared to freshly isolated monocytes. The addition of tacrolimus, but not MPA, resulted in an increase of the expression of M2
markers (CD16 and CD200R). (Data are plotted as the mean ±SEM; n = 5 *) p < 0.05; **) p < 0.01; ***) p < 0.001.
doi:10.1371/journal.pone.0170806.g007
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Fig 8. MPA and tacrolimus act differentially on the polarization of M1 and M2 macrophages. CD14+ isolated
monocytes were cultured for 4 days in the presence of either M-CSF and IFN-γ (left graphs), M-CSF and IL-4 (middle
graphs) or M-CSF and IL-10 (right graphs). In addition, vehicle, 10 ng/ml tacrolimus, 50 ng/ml tacrolimus, 200 ng/ml
tacrolimus or 10 μg/ml MPA were added to each culture condition. Tacrolimus changed the expression of M2 markers
under a M1-driven condition and decreases the expression of M1 markers under M2 conditions. MPA reduced the
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Finally, tacrolimus, but only at a concentration of 200 ng/ml, decreased CD14 and CD80
expression in the presence of IL-10 (M2c stimulus) (p< 0.05), while MPA decreased CD14
expression (p< 0.05) and did not affect the other markers (Fig 8, right column). Thus, both
tacrolimus and MPA increased the expression of M2 markers and decreased the expression of
M1 markers in the presence of different M1 and M2 stimuli.
Discussion
Cells from both the adaptive and innate immune system play an important role in the immune
response after SOT but the effects of the immunosuppressants tacrolimus and MPA on human
monocyte differentiation and functions have not been studied in-depth in previous studies.
This study demonstrates that 1) these drugs partially inhibit phosphorylation of signaling mol-
ecules involved in CD14+ monocyte activation, i.e., p38MAPK, ERK and Akt kinases, but 2)
have only limited effects on cytokine production, phagocytosis, phenotypic maturation, and
polarization (an overview of de results is given in S1 Table).
The inhibitory effect of tacrolimus on the calcineurin pathway and the effect of MPA on the
reduction of guanosine nucleotide synthesis in T-cells are well-known [19, 42]. Tacrolimus
also proved to inhibit p38MAPK phosphorylation in T-cells by more than 60%, which con-
trasts with the inhibition in monocytes [37]. As demonstrated here, in monocytes the
suppression of phosphorylation of intracellular signaling molecules was not more than 35%.
Tacrolimus partly inhibited p38 phosphorylation, while MPA mainly inhibited Akt phosphor-
ylation, although this inhibitory effect was also limited. Furthermore, phagocytosis and differ-
entiation were minimally influenced by tacrolimus and MPA, showing that monocytes could
be functional in the presence of tacrolimus and MPA. This may imply that cells of the innate
immune system are less susceptible for the immunosuppressive effects of tacrolimus or MPA
in comparison to cells of the adaptive immune system. The difference in inhibition between
the two immune responses could be explained by the working mechanism of the immunosup-
pressive drugs. For example, the main target of tacrolimus is the calcineurin pathway and it
may be that this pathway plays a more important role in T-cell activation than in monocyte
activation [43].
The limited effect of tacrolimus on p-ERK, a member of the MAPK pathway, may explain
the incomplete inhibition of monocyte activity and function as demonstrated in this study
[44]. P-ERK is involved in processes leading to IL-10 production (M2 macrophages), while
phosphorylated p38MAPK is essential for IL-12 production, which is in agreement with the
observed shift in macrophage polarization [45]. These data are in contradiction with the find-
ings reported by Chang et al. who described an inhibitory effect of tacrolimus on p-ERK but
not on p38MAPK phosphorylation [26]. However, in contrast to the present study in which
primary monocytes were investigated, the experiments by Chang et al. were performed with
LPS-stimulated monocytic leukemia cells (THP-1) and phosphorylation was measured by
means of Western blot. In the present study, phospho-specific flowcytometry was used to
quantify the biological effects of tacrolimus and MPA at the single-monocyte level, which is a
more sensitive tool for pharmacodynamic monitoring of drug effects [46, 47].
In contrast to tacrolimus, MPA (at a therapeutic concentration of 10 μg/ml) did not sup-
press the phosphorylation of p38MAPK, affected p-ERK to some degree, and had the largest
effect on p-Akt. MPA inhibits inosine monophosphate dehydrogenase, an enzyme that is
responsible for the de novo synthesis of guanosine nucleotides. As a consequence, the
expression of CD80 under a M2 inducing condition and increased M2 expression under IFN-γ stimulation. (Data are
plotted as the mean ±SEM n = 3 *) p < 0.05; **) p < 0.01; ***) p < 0.001.
doi:10.1371/journal.pone.0170806.g008
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proliferation of B and T-cells is inhibited. The only described effect of MPA on monocyte
function is the reduced production of IL-6 and IL-10, which are both downstream products of
the Akt/mTOR pathway [42, 48]. It has also been reported that IL-1β is a downstream mole-
cule of the AKT pathway [49, 50]. Here we found that MPA indeed partly inhibited IL-1β pro-
duction, suggesting that, in combination with the preferred inhibition of p-AKT, MPA affects
cytokine production via p-AKT.
The inhibition of signaling molecule phosphorylation by tacrolimus and MPA was smaller
than by the positive control SB203580, showing the limited effects of both immunosuppressive
drugs. However, the inhibition of phosphorylated p38MAPK by the positive control was also
not more than 50%. SB203580 was designed as an inhibitor of the phosphorylation induced by
p38MAPK on other molecules and on its own molecule, but cannot inhibit phosphorylation of
p38MAPK by other kinases [51]. Here, a significantly inhibitory effect of the MAPK inhibitor
on phosphorylated p38MAPK was found, which can probably be ascribed to of auto-phos-
phorylation in monocytes [52–54]. This alternative, non-canonical pathway for p38MAPK
phosphorylation could be another partial explanation for the incomplete inhibition of mono-
cytes by tacrolimus and MPA, besides the unaffected ERK phosphorylation.
The residual phosphorylation of the signaling molecules after tacrolimus or MPA treat-
ment may imply that monocyte functions, such as phagocytosis, remain intact. After SOT,
phagocytosis by monocytes/macrophages is one of the mechanisms to overcome infections.
Here, phagocytosis of E.coli-bacteria by monocytes was not affected by either tacrolimus or
MPA, suggesting that this monocyte function is still active during immunosuppressive drug
treatment.
The present study reports for the first time on the change of human macrophage matura-
tion and polarization in the presence of tacrolimus or MPA. Only high concentrations of
tacrolimus affect the maturation and change the polarization of macrophages to some extent.
Addition of tacrolimus or MPA did not affect the expression of CD80/CD64 (M1). However,
tacrolimus did stimulate the expression of CD16 and CD200R (M2). A similar change in polar-
ization by tacrolimus was previously found in mouse studies [55]. In addition, the effect of
tacrolimus and MPA on macrophage polarization in the presence of specific stimuli was inves-
tigated. A shift to an M2 phenotype was noticed when monocytes were cultured with tacroli-
mus or MPA in combination with IFN-γ, a cytokine that induces the differentiation of
monocytes into M1 macrophages. CD200R and CD163 (M2) expression was increased,
although the expression in M1 markers did not change. However, in the presence of M2-driv-
ing cytokines (IL-4 or IL-10) the CD80 marker for M1 macrophages was diminished by tacro-
limus, again pointing to induction of M2 differentiation. Altogether, these findings suggest
that tacrolimus and MPA have a limited effect on the function of monocytes by driving their
differentiation towards an M2 phenotype.
In order to reveal the clinical relevance of the limited effect of tacrolimus and MPA on
monocytes, the drug effects should be studied in a clinical setting. The role of monocytes in
alloreactivity after SOT includes the recognition of non-self antigens during the cellular
immune response and danger signals (PAMP’s) induced by ischemia-reperfusion injury [56,
57]. The humoral immune response includes the activation of Fcγ-receptors on monocytes by
allo-antibodies [8]. This immune response plays an important role in chronic antibody-medi-
ated rejection which is the main reason for chronic graft loss [58]. The residual monocyte
activity, a consequence of the limited effect of tacrolimus and MPA treatment, may partly
explain why chronic antibody-mediated rejection occurs after SOT. Furthermore, our previous
study on monocytes from kidney transplant patients showed a similarly limited functional
effect of immunosuppressive drugs on monocytes, suggesting that these cells can still play a
role in early post-transplant cellular immunity [59]. As readout in a new study, signaling
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protein phosphorylation could be measured, thereby relating the results to the outcomes of the
present paper. Here, we focused on the activation and function of CD14+ monocytes, without
dividing them into CD16-positive and -negative subsets, which show differential responses in
an inflammatory setting [60]. Future studies can focus on these subsets to reveal the effects of
immunosuppressive medication on these clinically relevant monocyte subsets. In addition,
studies in patients can unveil the effect of combination therapy on monocyte activation and
function, since the present study focused on the individual immunosuppressive drug effects. It
must also be considered that the role of macrophages may be different in different types of
organ transplantation. For example, cardiac macrophages are involved in tissue remodeling
and repair after myocardial infarction, while in the lungs their primary role is immune surveil-
lance. In the liver, Kupffer cells are involved in the breakdown of erythrocytes and the response
to infections, toxins, ischemia and other stress conditions [61, 62]. These cells are involved in
allograft rejection and may also play an important role in the development of immune toler-
ance after transplantation, suggesting that (partly) inhibition of these cells with tacrolimus
and MPA may will cause negative effects on graft survival [62]. In addition, macrophages are
known for their heterogeneity and it is possible that the composition of macrophage subsets is
different for different organs [63, 64]. For example, the polarization of tissue-resident macro-
phages is dependent on their local environment, suggesting high heterogeneity in macrophage
subsets between different organs [65]. Research is needed to show the functional effects of
tacrolimus and MPA on these cells. However, each macrophage does have targets for tacroli-
mus and MPA (e.g. calcineurin pathway and inosine monophosphate dehydrogenase) suggest-
ing that the difference in sensibility for these drugs between different macrophage subsets at
the single cell level may be limited.
In conclusion, tacrolimus and MPA hardly suppress monocyte signaling pathway activa-
tion. The residual phosphorylation of signaling proteins explains the limited effect of both
immunosuppressive drugs on cytokine production and phagocytosis, apart from monocyte
differentiation. This suggests that innate immune responses induced by monocytes after SOT
may still occur despite immunosuppressive therapy.
Supporting Information
S1 Fig. Monocyte differentiation experiments. (A) Schematic overview of the monocyte dif-
ferentiation experiments. For the first part of the differentiation study, monocytes were cul-
tured in the presence of M-SCF to induce maturation into macrophages. Next, the expression
of the surface markers for M1, M2a or M2c macrophages was determined after addition of
tacrolimus or MPA to the culture system. In the second part of the experiments, monocytes
were induced to polarize into a specific macrophage subtype. Addition of IFN-γ drives the
monocytes to polarize into M1 macrophages, IL-4 induces M2a and IL-10 increases M2c
macrophages. Then, tacrolimus and MPA were added to the cultured cells to determine the
capability of both drugs to change the expression of surface markers on M1, M2a and M2c dif-
ferentiated macrophages. (B) Validation of the differentiation assay. After addition of IFN-γ to
the culture medium, monocytes are stimulated to differentiate into M1 macrophages with a
significantly higher expression of the CD80 (p< 0.001) and CD64 (p< 0.001) compared to
monocytes cultured without the addition of extra cytokines. Culturing with IL-4 increased
the expression of CD200R (p< 0.01), lowered CD14 expression (p< 0.01), and thus drove the
differentiation into M2a macrophages. IL-10 stimulation induced the expression of CD163
(p< 0.01) and CD16 (p< 0.05) and resulted in M2c macrophage differentiation. (Data are
plotted as the mean ±SEM; n = 5) ) p< 0.05; ) p< 0.01; ) p< 0.001.
(TIF)
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